[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL192773A0 - Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol - Google Patents

Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol

Info

Publication number
IL192773A0
IL192773A0 IL192773A IL19277308A IL192773A0 IL 192773 A0 IL192773 A0 IL 192773A0 IL 192773 A IL192773 A IL 192773A IL 19277308 A IL19277308 A IL 19277308A IL 192773 A0 IL192773 A0 IL 192773A0
Authority
IL
Israel
Prior art keywords
alcohol
active ingredient
immediate release
pharmaceutical forms
forms resistant
Prior art date
Application number
IL192773A
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Publication of IL192773A0 publication Critical patent/IL192773A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL192773A 2006-02-16 2008-07-13 Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol IL192773A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0650566A FR2897267A1 (en) 2006-02-16 2006-02-16 MULTIMICROPARTICULAR PHARMACEUTICAL FORMS FOR PER OS ADMINISTRATION
PCT/EP2007/051528 WO2007093642A2 (en) 2006-02-16 2007-02-16 Microparticulate pharmaceutical forms resistant to immediate release of the active principle in the presence of alcohol

Publications (1)

Publication Number Publication Date
IL192773A0 true IL192773A0 (en) 2009-02-11

Family

ID=37103249

Family Applications (1)

Application Number Title Priority Date Filing Date
IL192773A IL192773A0 (en) 2006-02-16 2008-07-13 Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol

Country Status (13)

Country Link
EP (1) EP1986616B1 (en)
JP (1) JP5416974B2 (en)
KR (1) KR20080099270A (en)
CN (1) CN101378736B (en)
AU (1) AU2007216485A1 (en)
BR (1) BRPI0707859A2 (en)
CA (1) CA2649265C (en)
ES (1) ES2692450T3 (en)
FR (1) FR2897267A1 (en)
IL (1) IL192773A0 (en)
MX (1) MX2008010492A (en)
WO (1) WO2007093642A2 (en)
ZA (1) ZA200806118B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1492511E (en) 2002-04-09 2009-04-09 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
FR2936709B1 (en) 2008-10-02 2012-05-11 Ethypharm Sa ALCOHOL-RESISTANT TABLETS.
CN102238946B (en) * 2008-11-07 2014-11-26 株式会社三养生物制药 Pharmaceutical composition for the controlled release of methylphenidate
US10172805B2 (en) * 2008-11-18 2019-01-08 Ucb Biopharma Sprl Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
CN104083341A (en) * 2008-11-18 2014-10-08 Ucb医药有限公司 Prolonged Release Formulations Comprising an 2-Oxo-1-Pyrrolidine Derivate
BR112012001244A2 (en) 2009-07-22 2020-12-08 Gruünenthal Gmbh Tamper Resistant DOSAGE FORM, ITS PRODUCTION PROCESS, AND PACKAGING CONTAINING SUCH FORM
WO2011051324A1 (en) * 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv Radiolabelled pde10 ligands
ES2486791T3 (en) 2010-09-02 2014-08-19 Grünenthal GmbH Tamper resistant dosage form comprising an inorganic salt
EP2714015B1 (en) * 2011-06-01 2017-03-15 FMC Corporation Controlled release solid dose forms
CA2839126A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
DK2736495T3 (en) 2011-07-29 2017-11-13 Gruenenthal Gmbh ABUSE RESPONSIBLE TABLE THAT PROVIDES IMMEDIATE RELEASE OF MEDICINE
CN102512415B (en) * 2011-12-16 2013-07-31 山东齐都药业有限公司 Clopidogrel bisulfate medicine composition and preparation method
ES2692944T3 (en) 2012-04-18 2018-12-05 Grünenthal GmbH Pharmaceutical dosage form resistant to handling and resistant to rapid discharge of the dose
JP5960523B2 (en) * 2012-06-29 2016-08-02 旭化成株式会社 Solid formulation consisting of modified starch and dissolution control agent
EP3019157A1 (en) 2013-07-12 2016-05-18 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
RU2016147008A (en) * 2014-05-01 2018-06-04 Сан Фармасьютикал Индастриз Лимитед LIQUID METFORMINE COMPOSITIONS WITH LONG-LASTED RELEASE
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
WO2015166473A1 (en) * 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
JP6371463B2 (en) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Immediate release abuse deterrent liquid filler form
MX2017001332A (en) 2014-07-30 2017-08-02 Sun Pharmaceutical Ind Ltd Dual-chamber pack.
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CA2936748C (en) * 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (en) * 2016-07-22 2017-11-30 Flamel Ireland Ltd FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
ES2963929T3 (en) 2017-05-29 2024-04-03 Gruenenthal Gmbh Multiparticulate oral dosage form providing prolonged release of tapentadol
CN111278434A (en) * 2017-11-01 2020-06-12 埃奇蒙特医药信托有限公司 Alcohol-resistant oral pharmaceutical composition of lorazepam
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
GR1009751B (en) 2019-03-22 2020-05-29 "Φαρματεν Α.Β.Ε.Ε." Prolonged-release oxalic tapentadol -containing formula and preparation method thereof
GR1009791B (en) 2019-03-26 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Prolonged release tapentadol-containing formula - preparation method thereof
CN114340614B (en) * 2019-09-27 2024-01-16 广东东阳光药业股份有限公司 Oseltamivir preparation
CN112137990A (en) * 2020-11-04 2020-12-29 南京康川济医药科技有限公司 Epalrestat sustained-release preparation and preparation method thereof
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784390A (en) * 1971-07-23 1974-01-08 Hayashibara Biochem Lab Shaped bodies of pullulan and their use
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
ES2068762B1 (en) * 1993-07-21 1995-12-01 Lipotec Sa A NEW PHARMACEUTICAL PREPARATION TO IMPROVE THE BIOAVAILABILITY OF DRUGS OF DIFFICULT ABSORPTION AND PROCEDURE FOR THEIR OBTAINING.
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
DE19809719A1 (en) * 1998-03-06 1999-09-09 Roehm Gmbh Aqueous dispersion for binder and coating for medicine
CN1308523A (en) * 1998-04-27 2001-08-15 詹森药业有限公司 Pellets having a core coated with a lipid lowering agent and a polymer
JP3449253B2 (en) * 1998-10-29 2003-09-22 シオノギクオリカプス株式会社 Manufacturing method of hard capsule
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9919693D0 (en) * 1999-08-19 1999-10-20 Rhone Poulenc Rorer Ltd Process
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
SG126676A1 (en) * 2001-05-09 2007-01-30 Nanomaterials Tech Pte Ltd Process for the controlled production of organic particles
RU2004106619A (en) * 2001-08-06 2005-07-10 Эро-Селтик С.А. (Lu) COMPOSITIONS OF AN OPIOID AGONIST CONTAINING A RELEASABLE AND ISOLATED ANTAGONIST
GB0125604D0 (en) * 2001-10-25 2001-12-19 Glaxo Group Ltd Novel process
EP1417958A1 (en) * 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
FR2850576B1 (en) * 2003-02-05 2007-03-23 Ethypharm Sa COMPOSITION COMPRISING A MIXTURE OF ACTIVE INGREDIENTS AND PROCESS FOR PREPARING THE SAME
WO2004096177A1 (en) * 2003-05-02 2004-11-11 Globopharm Pharmazeutische Produktions- Und Handelsgesellschaft M.B.H. Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
DE60308828T2 (en) * 2003-05-20 2007-05-24 Ethypharm Oral pharmaceutical composition with sustained release
WO2005011666A1 (en) * 2003-08-05 2005-02-10 Ranbaxy Laboratories Limited Stable sustained release oral dosage form of gabapentin
US20050165038A1 (en) * 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
US20050249799A1 (en) * 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
JPWO2005084649A1 (en) * 2004-03-04 2007-11-29 武田薬品工業株式会社 Stable capsule
AU2005235369B2 (en) * 2004-04-22 2010-11-11 Acucort Ab Pharmaceutical compositions for acute glucocorticoid therapy
FR2872044B1 (en) * 2004-06-28 2007-06-29 Flamel Technologies Sa PHARMACEUTICAL FORMULATION BASED ON ANTIBIOTICS IN THE MICROCAPSULAR FORM
WO2006038226A2 (en) * 2004-10-08 2006-04-13 Rubicon Research Pvt. Ltd. Process for making a highly compressible controlled delivery compositions of metformin
FR2889810A1 (en) * 2005-05-24 2007-02-23 Flamel Technologies Sa ORAL MEDICINAL FORM, MICROPARTICULAR, ANTI-MEASUREMENT
GB0506982D0 (en) * 2005-04-06 2005-05-11 Mw Encap Ltd Abuse resistant capsules
FR2892937B1 (en) * 2005-11-10 2013-04-05 Flamel Tech Sa MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING

Also Published As

Publication number Publication date
EP1986616A2 (en) 2008-11-05
MX2008010492A (en) 2009-02-04
BRPI0707859A2 (en) 2011-05-10
WO2007093642A2 (en) 2007-08-23
ZA200806118B (en) 2009-04-29
AU2007216485A1 (en) 2007-08-23
KR20080099270A (en) 2008-11-12
CA2649265C (en) 2019-01-29
CN101378736A (en) 2009-03-04
CA2649265A1 (en) 2007-08-23
WO2007093642A3 (en) 2007-10-04
JP2009526825A (en) 2009-07-23
EP1986616B1 (en) 2018-08-15
ES2692450T3 (en) 2018-12-03
JP5416974B2 (en) 2014-02-12
CN101378736B (en) 2015-08-19
FR2897267A1 (en) 2007-08-17

Similar Documents

Publication Publication Date Title
IL192773A0 (en) Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol
EP2130552A4 (en) Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
EP2078731A4 (en) Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
ZA200900345B (en) Preparation of pharmaceutical formulations
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
HK1121970A1 (en) Sustained release pharmaceutical formulation comprising phenylephrine
IL204528A (en) Combined sustained and immediate release metadoxine pharmaceutical dosage forms
ZA201101477B (en) Co-crystals and pharmaceutical formulations comprising the same
HK1126667A1 (en) Self preserved aqueous pharmaceutical compositions
EP2112925A4 (en) Solid pharmaceutical dosage formulations
BRPI0908596A2 (en) prolonged release formulation and pharmaceutical composition
EP2379079A4 (en) Pharmaceutical formulations comprising voriconazole and processes for preparation thereof
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
EP1895991A4 (en) Modified release formulations of anti-irritability drugs
EP2045253A4 (en) alpha-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
GB0614586D0 (en) Pharmaceutical Formulation
UA103025C2 (en) Solid pharmaceutical formulation with delayed release
IL201465A0 (en) Self-precipitating pharmaceutical formulations for the modified release of active principle
DK200900115U1 (en) Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
EP2468771A4 (en) Pharmaceutical composition containing anti-hb-egf antibody as active ingredient
EP2002828A4 (en) Solid pharmaceutical preparation
ZA200810162B (en) Phenylphrine pulsed release formulations and pharmaceutical compositions
EP2322505A4 (en) 1-adamantylazetidin-2-one derivative and pharmaceutical preparation comprising same
HK1123998A1 (en) Pharmaceutical preparation containing garcinia acid and use thereof
ZA200901164B (en) Self preserved aqueous pharmaceutical compositions